MRK Forensic analysis

Trading Setup & Entry Strategy

• >Entry Zone: $112.50 – $113.50. Wait for a retest of the 10-day SMA ($112.59) following the recent breakout momentum. Avoid chasing at $114.24.
• >Stop Loss: $108.50 (Hard stop). Positioned below the lower Bollinger Band ($109.42) to account for volatility.
• >Position Sizing: 4% of total equity.
• >Scaling Strategy:
  1. >Enter 40% at $113.00.
  2. >Add 30% at $112.00 (if support holds).
  3. >Add 30% on a breakout above $115.50 (closing above 50-day SMA).
• >Take Profit: 50% at $121.00; 30% at $125.00; 20% trailing.
• >Risk/Reward: 1:2.4.

Recent Material Events (8-K Analysis)

• >April 30, 2026: Secured $6.0B credit facility to fund the Terns Pharmaceuticals acquisition ($6.7B). This is a capital-intensive move prioritizing oncology pipeline growth over immediate cash reserves.

Current News & Market Context

• >Catalysts: Recent positive data on ADC candidates in endometrial cancer and the collaboration with Exelixis for the Phase 3 STELLAR-316 trial. Merck’s Keytruda continues to dominate, highlighted by the failure of a Regeneron trial that failed to outperform Keytruda in melanoma.

Financial Health

• >10-Q Q1 2026: Heavy Q1 R&D charges ($12.59B vs $3.62B) due to acquisition accounting (Cidara). Adjusted for non-GAAP, underlying business remains strong in Oncology ($7.9B Keytruda revenue).
• >Cash Flow: Operating cash flow remains robust at $3.91B despite heavy M&A expenditure.

Technical Analysis & Trade Timing

• >RSI (14): 51.59 (Neutral). Room to run before overbought levels.
• >Trend: Bearish-Crossing is softening as price moves toward the 50-day SMA ($115.66). MACD is Bullish, suggesting the path of least resistance is higher once the $115.66 barrier is cleared.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days).
• >Max Hold: 7 days.
• >Catalyst: Focus on momentum continuation in the oncology franchise following the Exelixis collaboration news.

One-Liner Thesis: Merck is successfully transitioning its pipeline through aggressive ADC-focused M&A; a breakout above the 50-day SMA is imminent if oncology trial momentum persists.